{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:21:31Z","timestamp":1707524491838},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,30]]},"DOI":"10.7759\/cureus.20060","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T03:11:22Z","timestamp":1638328282000},"source":"Crossref","is-referenced-by-count":0,"title":["Erythrodysesthesia: An Unusual Complication With Trastuzumab Monotherapy"],"prefix":"10.7759","author":[{"given":"Andee L","family":"Fontenot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weldon J","family":"Furr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Husan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad W","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"NCI dictionary of cancer terms. (2010). Accessed. April 26, 2021: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/palmar-plantar-erythrodysesthesia."},{"key":"ref2","unstructured":"Common terminology criteria for adverse events (CTCAE), version 5.0, National Institutes of Health, National Cancer Institute. (2017). Accessed. April 26, 2021: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2011.10.002","article-title":"Trastuzumab-related palmar plantar erythrodysaesthesia","volume":"24","author":"Tho LM","year":"2012","unstructured":"Tho LM, Bose N, Robertson L, et al.. Trastuzumab-related palmar plantar erythrodysaesthesia. Clin Oncol (R Coll Radiol). 2012, 24:80-1. 10.1016\/j.clon.2011.10.002","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth AD","year":"2009","unstructured":"Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009, 77:257-71. 10.1159\/000258880","journal-title":"Oncology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07449.x","article-title":"The hand-foot-syndrome associated with medical tumor therapy-classification and management","volume":"8","author":"Degen A","year":"2010","unstructured":"Degen A, Alter M, Schenck F, et al.. The hand-foot-syndrome associated with medical tumor therapy-classification and management. JDDG: J Dtsch Dermatol Ges. 2010, 8:652-61. 10.1111\/j.1610-0387.2010.07449.x","journal-title":"JDDG: J Dtsch Dermatol Ges"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier J","year":"2008","unstructured":"Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol. 2008, 144:886-92. 10.1001\/archderm.144.7.886","journal-title":"Arch Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture ME","year":"2008","unstructured":"Lacouture ME, Wu S, Robert C, et al.. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008, 13:1001-11. 10.1634\/theoncologist.2008-0131","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq406","article-title":"Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer","volume":"22","author":"Wildiers H","year":"2011","unstructured":"Wildiers H, Neven P, Christiaens MR, et al.. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol. 2011, 22:588-94. 10.1093\/annonc\/mdq406","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8303","article-title":"Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study","volume":"28","author":"von Minckwitz G","year":"2010","unstructured":"von Minckwitz G, Rezai M, Loibl S, et al.. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010, 28:2015-23. 10.1200\/JCO.2009.23.8303","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200212000-00015","article-title":"Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer","volume":"25","author":"Eich D","year":"2002","unstructured":"Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Krieg T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol. 2002, 25:599-602. 10.1097\/00000421-200212000-00015","journal-title":"Am J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos R","year":"2008","unstructured":"von Moos R, Thuerlimann BJ, Aapro M, et al.. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008, 44:781-90. 10.1016\/j.ejca.2008.01.028","journal-title":"Eur J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)","volume":"18","author":"Lorusso D","year":"2007","unstructured":"Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann Oncol. 2007, 18:1159-64. 10.1093\/annonc\/mdl477","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2006.10.004","article-title":"Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre","volume":"11","author":"Webster-Gandy JD","year":"2007","unstructured":"Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007, 11:238-46. 10.1016\/j.ejon.2006.10.004","journal-title":"Eur J Oncol Nurs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO Quality of Life Working Group","volume":"33","author":"Hofheinz RD","year":"2015","unstructured":"Hofheinz RD, Gencer D, Schulz H, et al.. Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO Quality of Life Working Group. J Clin Oncol. 2015, 33:2444-9. 10.1200\/JCO.2014.60.4587","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren Z","year":"2015","unstructured":"Ren Z, Zhu K, Kang H, et al.. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015, 33:894-900. 10.1200\/JCO.2013.52.9651","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20073","article-title":"Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma","volume":"100","author":"Hau P","year":"2004","unstructured":"Hau P, Fabel K, Baumgart U, et al.. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer. 2004, 100:1199-207. 10.1002\/cncr.20073","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1807","article-title":"Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kang YK","year":"2010","unstructured":"Kang YK, Lee SS, Yoon DH, et al.. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010, 28:3824-9. 10.1200\/JCO.2010.29.1807","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.021","article-title":"Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling","volume":"108","author":"Mangili G","year":"2008","unstructured":"Mangili G, Petrone M, Gentile C, De Marzi P, Vigan\u00f2 R, Rabaiotti E. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol. 2008, 108:332-5. 10.1016\/j.ygyno.2007.10.021","journal-title":"Gynecol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/71031-erythrodysesthesia-an-unusual-complication-with-trastuzumab-monotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:32Z","timestamp":1707507092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/71031-erythrodysesthesia-an-unusual-complication-with-trastuzumab-monotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.20060","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}